Health Care & Life Sciences » Biotechnology | Uni-Bio Science Group Ltd.

Uni-Bio Science Group Ltd. | Balance Sheet

Fiscal year is January-December. All values HKD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
14,134.00
138,126.00
110,014.00
78,117.00
121,281.00
38,786
Total Accounts Receivable
48,194.00
35,790.00
39,875.00
38,581.00
67,329.00
44,479
Inventories
4,924.00
7,899.00
9,064.00
13,052.00
13,548.00
18,517
Other Current Assets
1,087.00
2,536.00
1,975.00
1,669.00
2,830.00
1,488
Total Current Assets
68,339.00
184,351.00
160,928.00
131,419.00
204,988.00
103,270
Net Property, Plant & Equipment
182,838.00
141,502.00
125,913.00
107,544.00
78,112.00
57,951
Total Investments and Advances
35,347.00
26,001.00
22,549.00
22,245.00
26,605.00
24,350
Intangible Assets
574,833.00
230,245.00
230,520.00
220,471.00
63,313.00
46,021
Other Assets
16,436.00
14,569.00
17,046.00
15,642.00
17,171.00
10,856
Total Assets
877,793.00
596,668.00
556,956.00
497,321.00
390,189.00
242,448
ST Debt & Current Portion LT Debt
32,012.00
-
9,662.00
10,990.00
-
Accounts Payable
1,015.00
3,448.00
2,679.00
7,188.00
9,002.00
Income Tax Payable
2,638.00
2,808.00
2,532.00
2,281.00
2,422.00
Other Current Liabilities
39,523.00
26,767.00
34,570.00
29,509.00
34,204.00
Total Current Liabilities
75,188.00
33,023.00
49,443.00
49,968.00
45,628.00
Long-Term Debt
97,801.00
-
-
-
-
Deferred Taxes
1,442.00
520.00
853.00
949.00
1,408.00
Other Liabilities
3,854.00
-
-
-
-
Total Liabilities
178,285.00
33,543.00
50,296.00
50,917.00
47,036.00
Common Equity (Total)
699,508.00
563,125.00
506,660.00
446,404.00
343,153.00
Total Shareholders' Equity
699,508.00
563,125.00
506,660.00
446,404.00
343,153.00
Total Equity
699,508.00
563,125.00
506,660.00
446,404.00
343,153.00
Liabilities & Shareholders' Equity
877,793.00
596,668.00
556,956.00
497,321.00
390,189.00

About Uni-Bio Science Group

View Profile
Address
Unit 502, 5/F
Hong Kong
Hong Kong
Employees -
Website http://www.uni-bioscience.com
Updated 07/08/2019
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. It operates through the following segments: Manufacture and Sale of in-house chemical pharmaceutical products; Manufacture and sale of in-house biological pharmaceutical products; Industrialization of in-house biological pipeline; and Third Party pharmaceutical products. The company was founded in 2001 and is headquartered in Hong Kong.